Summary
Boston Scientific Corporation (BSX) reported robust financial results for the second quarter and first six months of 2025, demonstrating significant year-over-year growth in net sales and profitability. Net sales increased by 22.8% in Q2 2025 to $5.061 billion, driven by strong operational growth of 21.6% and contributions from recent acquisitions. The company's net income attributable to common stockholders rose substantially to $797 million in Q2 2025, up from $324 million in the prior year period. Key growth drivers included the Electrophysiology business unit, propelled by the adoption of the Farapulse™ Pulsed Field Ablation System, and strong performance across the Cardiovascular and MedSurg segments. The company also made strategic acquisitions during the period, including Anrei Medical, SoniVie Ltd., Intera Oncology®, and Bolt Medical, Inc., which are expected to enhance its product portfolio and market position. Despite some headwinds such as increased R&D expenses and restructuring charges, BSX maintains a solid financial position and expects continued growth.
Financial Highlights
49 data points| Revenue | $5.06B |
| Cost of Revenue | $1.64B |
| Gross Profit | $3.42B |
| SG&A Expenses | $1.72B |
| Operating Expenses | $2.60B |
| Operating Income | $819.00M |
| Interest Expense | $90.00M |
| Net Income | $795.00M |
| EPS (Basic) | $0.54 |
| EPS (Diluted) | $0.53 |
| Shares Outstanding (Basic) | 1.48B |
| Shares Outstanding (Diluted) | 1.49B |
Key Highlights
- 1Net sales for Q2 2025 surged to $5.061 billion, a 22.8% increase year-over-year, driven by strong operational and organic growth, as well as contributions from acquisitions.
- 2Net income attributable to common stockholders reached $797 million in Q2 2025, a significant increase from $324 million in Q2 2024, reflecting improved profitability.
- 3The Electrophysiology business unit, particularly the Farapulse™ PFA System, was a major growth driver, demonstrating strong commercial execution and market adoption.
- 4The company completed several strategic acquisitions in the first half of 2025, including Anrei Medical, SoniVie, Intera Oncology®, and Bolt Medical, aimed at expanding its product offerings and market reach.
- 5Research and Development (R&D) expenses increased significantly, reflecting ongoing investment in innovation and a robust pipeline of new products.
- 6Despite a decrease in gross profit margin due to inventory charges and other period expenses, overall profitability improved.
- 7Boston Scientific reported strong compliance with its financial covenant (leverage ratio of 2.16x vs. 4.75x maximum permitted), indicating a healthy balance sheet and financial flexibility.